In Vivo Models: Complex Surgery & Gene Editing | HuaTeng Biotech

Created on 10.23

In Vivo Models: Complex Surgery & Gene Editing | HuaTeng Biotech

Translational research lives or dies on the quality of its in vivo models. A device engineer can simulate a thousand load cycles in silico, and a molecule biologist can validate a target in a dish, but neither can predict how a human body will respond to an implant, a delivery catheter, or a regenerative therapy until that intervention is tested in a living system with real anatomy, real healing biology, and real hemodynamics. Sponsors preparing FDA, CE, or NMPA submissions increasingly understand that a poorly chosen species or a sloppy surgical protocol generates data regulators will question and clinicians will not trust. That is why in vivo models have become a strategic asset rather than a commodity line item in preclinical programs.
This is precisely the territory that HuaTeng Biotechoccupies. The company builds customized large animal models and complex surgical models for medical device, pharmaceutical, biologic, biomaterial, and regenerative medicine developers, combining species-specific surgical expertise with gene-editing capability and standardized perioperative care. Rather than offering a static catalog of off-the-shelf animals, the team designs each model around the clinical question, the intended endpoint, and the regulatory pathway the sponsor is pursuing. The result is preclinical research data that holds up under scrutiny from regulators, investors, and clinical collaborators alike.

Why Choose HuaTeng Biotech for In Vivo Models?

HuaTeng Biotech specializes exclusively in customized in vivo models, surgical modeling, and the preclinical research services that surround them. Its platform spans pig, dog, sheep, and rabbit model systems, which together cover the size, anatomy, and physiology range most translational programs need across cardiovascular, orthopedic, vascular, wound, and metabolic indications. Complex surgical and interventional expertise sits at the center of the offering, so sponsors do not have to coordinate separately between an animal vendor, a surgical contractor, and an imaging lab. Gene-edited large animal customization is available in-house, which lets a program move from a wild-type surgical model to a disease-relevant genetic background without changing partners. Orthopedic, vascular, wound, and PAD modeling are treated as core competencies rather than occasional side projects.
The competitive advantage is less about equipment lists and more about study design discipline. Every project begins with a tailored design conversation that weighs translational species selection against endpoint requirements, animal numbers, timelines, and cost. Experienced surgical teams perform the procedures themselves, which reduces inter-operator variability that otherwise erodes statistical power. Standardized perioperative care and monitoring protocols keep animals stable through recovery, protecting both welfare outcomes and data quality. Clear project communication and milestone-based reporting mean sponsors see progress rather than silence between kickoff and final report. Applications across medical devices, pharmaceuticals, biologics, biomaterials, regenerative medicine, and even surgical technique training all draw on the same underlying infrastructure.

Complex Surgical Models in Pigs, Dogs, Sheep, and Rabbits

Species selection is the single most consequential decision in surgical model development, because the wrong species cannot be rescued by better statistics. Anatomy, organ size relative to the target device, healing rate, coagulation profile, and the regulatory precedent for a given indication all interact. HuaTeng Biotech maintains validated platforms across four species so that the choice follows the science rather than the convenience of what happens to be available. The sections below summarize how each platform is typically deployed.

Pig Models for Cardiovascular, Abdominal, Orthopedic, and Wound Research

Pigs remain the workhorse species for large animal models in device evaluation, and for good reason. Cardiovascular anatomy, coronary artery caliber, and hemodynamic behavior closely mirror human physiology, which makes pigs the default choice for stent, valve, and vascular graft studies. Abdominal procedures benefit from comparable organ size and surgical planes, while orthopedic and wound work leverages skin and bone characteristics that behave predictably under intervention. Interventional research in pigs is well supported by fluoroscopic and catheter-based workflows that map directly onto clinical technique. The species also tolerates repeated imaging and follow-up procedures, which matters for long-endpoint studies.

Dog Models for Orthopedic, Vascular, and Device Studies

Dog models deliver value where species-specific anatomy and physiology are genuinely relevant to the clinical question. Orthopedic research often benefits from bone geometry and joint mechanics that support implant and fixation evaluation with strong translational precedent. Vascular studies in dogs are well established in the literature, giving sponsors a defensible reference base for regulatory discussion. Surgical device studies that require a particular vessel caliber or limb anatomy can be matched to canine anatomy more precisely than to other species. HuaTeng Biotech's teams are experienced in canine perioperative management, which is a frequent weak point when sponsors attempt these studies in-house.

Sheep Models for Orthopedic, Cardiovascular, and Soft-Tissue Implants

Sheep are a strong translational choice for orthopedic implants, cardiovascular devices, and soft-tissue reconstruction. Body size supports human-scale implants, which means a device tested in sheep can often be the same product configuration intended for clinical use. Bone remodeling in sheep provides a meaningful healing model for fixation, defect repair, and cartilage-related work. Cardiovascular applications benefit from accessible vasculature and reliable anesthesia protocols. HuaTeng Biotech uses sheep where implant scale and long-term tolerance are the dominant concerns.

Rabbit Models for Focused Surgical and Biomaterial Studies

Rabbit models offer an efficient middle ground for focused preclinical research and biomaterial screening. Orthopedic defect studies, wound healing assessments, and vascular evaluations can be run at lower cost and faster timelines than large species while retaining a mammalian healing response. Rabbits are also well suited to early feasibility work where a sponsor needs directional data before committing to larger studies. HuaTeng Biotech uses rabbit platforms as a stepping stone that de-risks later large animal models.

Interventional Model Development

Catheter-based and image-guided procedures now dominate many clinical specialties, and in vivo models must keep pace. HuaTeng Biotech develops interventional models that replicate clinical access routes, device tracking, deployment mechanics, and procedural endpoints. Fluoroscopic and imaging support allows sponsors to evaluate device placement, delivery system performance, and vascular access in a realistic anatomy. Species and vessel selection are aligned to the intended clinical use case so that catheter reach, crossing behavior, and deployment forces reflect what a clinician will actually encounter. Integration with surgical, imaging, and endpoint analysis workflows keeps a single project team accountable from procedure through histology.
Well-constructed interventional models also support training and usability work alongside formal preclinical evaluation. Procedural endpoints such as acute success, vessel patency, and device positioning can be captured in real time and preserved for later review. Where chronic follow-up is required, the same team manages recovery, monitoring, and scheduled imaging so longitudinal data are collected consistently.

Orthopedic, Vascular, Wound, and PAD Surgical Modeling

Orthopedic Models

Orthopedic modeling covers bone defect creation, implant and fixation evaluation, cartilage repair, and joint-related surgical work. HuaTeng Biotech designs these surgical model development projects around the endpoint the sponsor actually needs, whether that is histology, imaging, biomechanics, or clinical scoring. Fixation stability and defect geometry are controlled so that outcomes can be attributed to the intervention rather than to surgical technique. Perioperative monitoring and standardized recovery protocols protect data quality.

Vascular Models

Vascular work includes vessel injury, bypass construction, thrombosis modeling, and vascular device evaluation. Species selection is driven by vessel caliber and hemodynamic similarity to the target clinical anatomy. Endpoint design typically combines angiography, flow measurement, and histopathology so that patency and remodeling can be assessed together. These in vivo models are frequently paired with interventional workflows to mirror clinical deployment. The result is a dataset that speaks directly to device safety and performance.

Wound and Regenerative Therapy Models

Wound models address both acute and chronic healing scenarios, which behave very differently and require different designs. HuaTeng Biotech supports biomaterial placement, regenerative therapy assessment, and healing kinetics studies with standardized wound creation and consistent dressing protocols. Quantitative endpoints such as planimetry, histology, and biomarker analysis are built into the design from the start. Careful control of wound location and size reduces the variability that most often undermines these studies. Sponsors in regenerative medicine use these platforms to compare candidate formulations under comparable conditions.

PAD Models

Peripheral artery disease modeling supports ischemia, revascularization, and therapeutic development programs. PAD models demand careful attention to occlusion technique, collateral anatomy, and follow-up timing, because the ischemic trajectory determines whether a therapy can show benefit. HuaTeng Biotech designs PAD studies with defined perfusion endpoints, imaging schedules, and tissue-level analysis. Species and vessel selection are matched to the clinical scenario the sponsor is targeting. Combined with surgical and interventional capability, this creates a coherent path from feasibility through pivotal preclinical work.

Gene-Edited Large Animal Customization

Genetic background can make or break a translational study, and off-the-shelf animals rarely carry the disease-relevant genotype a modern program needs. HuaTeng Biotech offers custom gene-edited pig, dog, sheep, and rabbit models for disease modeling, target validation, and translational research. The workflow begins with target consultation and gene-editing strategy, then progresses through model generation, breeding where required, and delivery of study-ready animals. Editing strategy is chosen to match the biology, the species, and the timeline rather than applying a single method to every project. Sponsors can then layer surgical phenotyping, imaging, and endpoint analysis onto a genetically defined background.
The practical payoff appears in cardiovascular, metabolic, orthopedic, and regenerative medicine research, where a genetic predisposition can transform a marginal phenotype into a measurable one. Gene-edited large animal models also reduce the animal numbers needed to detect an effect, which is both a welfare and an economic argument. HuaTeng Biotech coordinates editing, surgery, and analysis under one project structure so that genotype and phenotype data are interpreted together. Researchers interested in the broader model catalog can explore theAnimal Models platform for related disease and surgical systems.

Our In Vivo Model Workflow

The workflow is deliberately structured to eliminate the gaps where preclinical projects usually stall. Step one is scientific consultation and feasibility assessment, where the clinical question, endpoint, and constraints are defined openly. Step two is species, model, and surgical protocol design, including animal numbers and a realistic timeline. Step three is ethics and welfare-compliant model development and surgery, conducted under approved protocols and standardized technique. Step four covers perioperative care, monitoring, and data collection, which is where variability is contained or introduced. Step five delivers endpoint analysis, reporting, and post-study support, including histopathology and image interpretation where needed.
Each stage produces a review point, so sponsors see interim results and can adjust rather than discovering a mismatch at final report. Surgical, imaging, and analytic teams work from a shared protocol, which keeps endpoint definitions consistent across the study. Where a program spans device testing and drug development, the same infrastructure supports both through CRO Services and dedicated Medical Device Testing In Vivo pathways.

Quality, Welfare, and Translational Relevance

Animal welfare and data quality are the same problem viewed from two angles. HuaTeng Biotech operates under standardized procedures, approved protocols, and species-specific care routines, because stressed or poorly managed animals produce noisy endpoints. Experienced surgical teams reduce variability by keeping technique consistent across operators and cohorts. Translational endpoint selection is treated as a design decision, not an afterthought, so that the measurements collected will actually support regulatory and commercial decisions. Reproducible study conduct is documented throughout, which matters when a reviewer asks how a result was generated.
Sponsors can review certifications, platform details, and company background through About Us and the Resources section, which outlines imaging, histopathology, and molecular capabilities. For programs that also require pharmacokinetic or safety work, Preclinical Drug Development Solutions extend the same standards into GLP-oriented assessment. Recent activity and platform updates are published in Company News.

Start Your Custom In Vivo Model Project

If your program needs a surgical model that reflects a real clinical scenario, the fastest path forward is a direct technical conversation. HuaTeng Biotech invites researchers to discuss species selection, surgical model design, interventional requirements, and gene-editing strategy before any commitment is made. Bring your endpoint list, your regulatory context, and your timeline, and the team will map a feasible design against them. You can submit details through the Contact Us page, and the Guangzhou and Hong Kong offices will route your inquiry to the appropriate scientific lead.

Frequently Asked Questions (FAQ)

What in vivo models does HuaTeng Biotech offer?

The company offers customized in vivo models across pig, dog, sheep, and rabbit platforms, covering complex surgical models, interventional procedures, orthopedic and vascular work, wound healing, PAD modeling, and gene-edited large animal customization. Each model is designed around the sponsor's endpoint and regulatory pathway rather than selected from a fixed catalog.

Can you customize pig, dog, sheep, and rabbit surgical models?

Yes. Species, procedure, device configuration, animal numbers, and follow-up schedule are all defined during study design. The team matches anatomy and physiology to the clinical use case, then builds a surgical protocol, perioperative care plan, and endpoint package that fit the program's timeline and budget.

Do you support interventional, orthopedic, vascular, wound, and PAD models?

All five are core capabilities. Interventional models use image-guided, catheter-based workflows; orthopedic models cover bone defects, implants, fixation, and cartilage; vascular models address injury, bypass, and thrombosis; wound models span acute and chronic healing; and PAD models support ischemia and revascularization research with defined perfusion endpoints.

How does gene-edited large animal customization work?

The process starts with target consultation and a gene-editing strategy tailored to the species and biology, followed by model generation and delivery of study-ready animals. Surgical phenotyping, imaging, and endpoint analysis can then be layered onto the genetically defined background, which is especially useful in cardiovascular, metabolic, orthopedic, and regenerative medicine programs.

How do I choose the right species for my in vivo models?

Selection depends on anatomy and organ size relative to the device, healing rate, coagulation and hemodynamic similarity to humans, endpoint requirements, and regulatory precedent for the indication. A short technical consultation with the HuaTeng Biotech team usually resolves the question before a protocol is written.

Are your in vivo models suitable for FDA, CE, and NMPA submissions?

Studies are designed with regulatory context in mind, using standardized procedures, documented conduct, and translational endpoints that reviewers expect to see. Programs intended for device or drug submissions can be structured to align with the specific evidence expectations of each market.

How long does a custom surgical model project take?

Timelines vary with species, surgical complexity, and follow-up duration. Acute interventional studies can be completed relatively quickly, while chronic orthopedic or gene-edited programs require longer generation and observation windows. A realistic schedule is agreed during feasibility assessment.

What perioperative care and welfare standards apply?

All work follows approved ethics protocols, species-specific care routines, and standardized monitoring during recovery. Welfare discipline is treated as inseparable from data quality, because consistent handling and pain management directly reduce endpoint variability.

How do I start an in vivo model project with HuaTeng Biotech?

Submit your study outline, endpoints, and timeline through the Contact Us page, and the scientific team will respond with a feasibility view, a proposed species and model design, and next steps. No commitment is required to begin the technical discussion.
Contact
Leave your information and we will contact you.

Copyright ©️ 2022, NetEase Zhuyou(and its affiliates as applicable). All Rights Reserved.

Company

Collections

About

Follow us

Team&Conditions

Work With Us

Featured Products

News

LinkedIn

All products

Shop

Facebook

Twitter

phone
Email